Global Oncology Academy

Study Shows Importance of Comprehensive Genomic Profiling for NSCLC

ReachMD Healthcare Image
RestartResume

What do we need to know about comprehensive genomic profiling and CGP-directed therapies for NSCLC patients?

  • Overview

    This episode will recap updates from the 2023 ASCO Annual Meeting regarding the abstract on comprehensive genomic profiling for non-small cell lung cancer (NSCLC). Join Dr. Vivek Subbiah, Chief of Early Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, to learn more.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free